WaveMan
WaveMan · Company
LIPO · Lipella Pharmaceuticals Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LIPO Lipella Pharmaceuticals (LIPO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001347242
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Lipella Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for LIPELLA PHARMACEUTICALS INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Kaufman Jonathan H
See remarks below.
BUY
2024-05-15 SECtraded 2024-05-14
10,000
$7.6K
-100.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 19, 2024.
  • -15.1% median (-15.1% mean) 90-day return after 2 previous buys.
  • The trade is 1.1% of the 898,849 shares held after it.
  • No other insider bought within 30 days.
Insider activity: See remarks below. Kaufman Jonathan H bought about $7.6K of LIPO on May 14, 2024.
Kaufman Jonathan H
See remarks below.
BUY
2024-03-19 SEC
25,000
$21.8K
-100.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 18, 2024.
  • The trade is 2.8% of the 888,849 shares held after it.
  • No other insider bought within 30 days.
Insider activity: See remarks below. Kaufman Jonathan H bought about $21.8K of LIPO on Mar 19, 2024.
Kaufman Jonathan H
See remarks below.
BUY
2024-03-19 SECtraded 2024-03-18
30,000
$23.7K
-100.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.5% of the 863,849 shares held after it.
  • No other insider bought within 30 days.
Insider activity: See remarks below. Kaufman Jonathan H bought about $23.7K of LIPO on Mar 18, 2024, the largest insider purchase at the company on our record.
3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+19.3% year over year
more than 66% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 92% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LIPO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.9%12M
-100%-67%-33%+0%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LIPO: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in LIPO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LIPO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LIPO financials

Revenue growth
+19.3%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$389.8K
four quarters, 2024-10-01 to 2025-09-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.02x
long-term debt only, 2021-12-31 (45 months older than the period end); equity 2025-09-30
Cash flow to debt
-157.36x
TTM operating cash flow over long-term debt only, 2021-12-31 (45 months older than the period end)
Return on equity
-361.8%
TTM net income over average of 2024-09-30 and 2025-09-30
Return on assets
-236.4%
TTM net income over average of 2024-09-30 and 2025-09-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-341.7%
operating income (EBIT proxy) over average of 2024-09-30 and 2025-09-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
-$1.8M
market value at close 2026-10-23 on 2025-11-13 shares, plus long-term debt only, 2021-12-31 (45 months older than the period end), minus cash 2025-09-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Revenue$536.4K$449.6K$184.2K$259.3K
Operating income-$5.1M-$4.7M-$2.6M-$1.9M
Net income-$5.0M-$4.6M-$2.6M-$1.9M
EPS (diluted)-4.79-6.16-0.64-0.55
Operating cash flow-$4.0M-$3.2M-$1.8M-$989.3K
Cash$2.2M$3.3M$5.1M$1.4M
Long-term debtn/an/an/a$30.3K
SEC XBRL, fiscal years, as known on 2026-10-27

LIPO Stock Sonar score 4/7 axes

Find similar shapesCompare

LIPO ranks highest on risk and compliance (95th percentile) and growth (66th), and lowest on profitability (8th), among Pharma & Biotech peers.

Profitability
8
Inputs
  • Return on equity-361.8% · 11 pct, sector of 545
  • Return on assets-236.4% · 9 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-341.7% · 5 pct, sector of 576
Financial health
39
Inputs
  • Debt to equity0.02x · 71 pct, sector of 352
  • Cash flow to debt-157.36x · 6 pct, sector of 371
Growth
66
Inputs
  • Revenue growth, YoY+19.3% · 66 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
95
Inputs
  • Short interest, % of float+0.0% · 95 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies